Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
How do you approach patients with lymph node only recurrences in the setting of previously resected colon cancer that are not amenable to biopsy?
Do we wait and watch vs start treatment based on ctDNA results?
Related Questions
Would you rechallenge with cabozantinib in a patient with HCC after the development of a 6 mm gastrohepatic fistula without perforation or communication with the peritoneal cavity?
Are you incorporating TTFields into treatment protocols for locally advanced pancreatic cancer based on the PANOVA-3 study?
What treatments, after appropriate dose reductions/delays, do you offer for patients with oxaliplatin-induced cold allodynia/dysesthesia?
In a patient with esophageal cancer with lymph node involvement, would you consider treating with definitive chemo-radiation if they have a single area of retroperitoneal metastasis?
What adjuvant treatment would you offer a patient with adenocarcinoma of the mid-esophagus cT2N0M0 who underwent upfront esophagectomy, which showed T2N1 disease with negative margins?
How do you manage oxaliplatin-induced splenomegaly?
If using GCSF with mFOLFIRINOX, would you ever use it during day 1?
Are there long-term toxicity and QOL considerations for patients receiving nivo/ipi compared to checkpoint monotherapy that would impact your treatment decisions for first line metastatic MSI-H/dMMR CRC?
Do you incorporate the ALASCCA trial into your clinical practice and perform NGS on all early stage colon cancer patients to determine if adjuvant aspirin would be beneficial?
What is the appropriate monitoring for an incidental low-grade rectal neuroendocrine tumor resected endoscopically with positive margins?